Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T19:18:05.434Z.
Calculation as of: 2026-10-06T19:18:05.434Z.
Quote observation: 2026-10-06T19:14:55.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4553d85706fed5bac33927ddb0c45062b9ca990621471d16f8faa1ad8920ffc8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$166.34M
PS Ratio
N/A
TTM Avg
3112093.93
3Y Avg
3112093.93
5Y Avg
3112093.93
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PepGen Inc. (PEPG) | $160.13M | N/A | N/A | N/A | N/A |
| Minerva Neurosciences, Inc. (NERV)vs › | $160.02M | N/A | 2.98 | 2.98 | 2.98 |
| LifeMD, Inc. (LFMDP)vs › | $159.22M | 0.78 | 4.69 | 4.83 | 4.86 |
| Coherus Oncology, Inc. (CHRS)vs › | $162.23M | 3.18 | 3.40 | 1.68 | 2.05 |
| Quanterix Corporation (QTRX)vs › | $162.80M | 1.06 | 1.56 | 3.32 | 5.03 |
| Inogen, Inc. (INGN)vs › | $156.90M | 0.44 | 0.50 | 0.55 | 0.91 |
| OptimizeRx Corp. (OPRX)vs › | $165.47M | 1.68 | 1.70 | 2.13 | 4.88 |
| Neuronetics, Inc. (STIM)vs › | $154.14M | 0.99 | 0.94 | 1.18 | 1.35 |
| Nkarta, Inc. (NKTX)vs › | $166.34M | N/A | 3112093.93 | 3112093.93 | 3112093.93 |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $152.82M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-12 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-04 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-12 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
